Central Precocious Puberty Guideline Favors Observation and Selective Testing
Key Takeaways
- The Endocrine Society’s first clinical practice guideline on central precocious puberty provided 10 recommendations and framed diagnosis and treatment around observation and individualized care.
- The guideline described two observation pathways: girls with thelarche at ages 7 to 8 years may undergo periodic physical examinations every 4 to 6 months, while girls younger than 7 years with initial breast development may undergo 4 to 6 months of observation before diagnostic evaluation.
- Routine brain MRI was not recommended for older children with central precocious puberty and no central nervous system findings, routine genetic testing was not recommended for all children, and gonadotropin-releasing hormone agonists were described as first-line treatment for most children although some named subgroups may not achieve net benefit.
In the diagnostic section, the guideline directed girls with thelarche at ages 7 to 8 years toward periodic physical examinations every 4 to 6 months instead of immediate laboratory or radiologic imaging, and it described girls younger than 7 years with initial breast development as candidates for 4 to 6 months of observation before diagnostic evaluation. The authors also reported that routine brain MRI was not recommended for older children with central precocious puberty who had no central nervous system findings, and that routine genetic testing was not recommended for all children, with family history identified as a context for selective testing and cost and access noted among the considerations. Overall, the diagnostic recommendations centered on close follow-up and selective workup.
For treatment, gonadotropin-releasing hormone agonists were described as first-line therapy for most children, with Stephanie A. Roberts identifying adult height as the main outcome underlying that recommendation. The guideline named girls aged 7 to 8 years with slow pubertal progression and girls or boys already in peak pubertal growth spurt as examples that may not achieve net benefit.
Latronico and colleagues’ central precocious puberty recommendations also described biochemical testing during therapy only if treatment failure is a concern, a recommendation that children who are to receive a long-acting gonadotropin-releasing hormone agonist start with that medication rather than a monthly drug, and no add-on growth hormone because no adult-height improvement was described with the combination. Reported stopping ranges were chronological age 10 to 11 years for girls and 11 to 12 years for boys, or bone age 11 to 12 years for girls and 12 to 13 years for boys, with discontinuation described as individualized; Roberts also highlighted remaining evidence gaps in younger children, outcomes beyond growth including metabolic, cardiovascular, and oncologic outcomes, and more data in boys, for whom some recommendations excluded boys or extrapolated data to them.
Clinician Questions
Which girls with early breast development were described as candidates for observation before immediate diagnostic testing?
In the diagnostic section, girls with thelarche at ages 7 to 8 years were described as undergoing periodic physical examinations every 4 to 6 months instead of immediate laboratory or radiologic imaging, and girls younger than 7 years with initial breast development were described as undergoing 4 to 6 months of observation before diagnostic evaluation.
When did the guideline say brain MRI and genetic testing are not routinely recommended in central precocious puberty?
In central precocious puberty, routine brain MRI was not recommended for older children who had no central nervous system findings, and routine genetic testing was not recommended for all children; the guideline identified family history of the disorder as the context for selective genetic testing and noted cost and access among the considerations.
What stopping-age ranges were reported for gonadotropin-releasing hormone agonist therapy in children with central precocious puberty?
For children with central precocious puberty receiving gonadotropin-releasing hormone agonist therapy, the reported discontinuation ranges were chronological age 10 to 11 years for girls and 11 to 12 years for boys, or bone age 11 to 12 years for girls and 12 to 13 years for boys, and the guideline described the decision to stop therapy as individualized.